v3.25.4
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) - USD ($)
$ in Millions
 12 Months Ended 21 Months Ended 27 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
Dec. 31, 2025
Restructuring Cost and Reserve [Line Items]          
Restructuring charge (credit) [1] $ 1,092 $ 1,987 $ 1,968    
Other Restructuring [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring charge (credit) 59 403      
Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring charge (credit) 691 1,800 1,500    
Realigning Our Cost Base Program - Initial Phase [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 4,700     $ 4,700 $ 4,700
Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 3,100     3,100 3,100
Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Other Restructuring [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 600     600 600
Realigning Our Cost Base Program [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 5,300     5,300 5,300
Restructuring costs incurred to date 4,200     4,200 4,200
Realigning Our Cost Base Program [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 3,700     3,700 3,700
Restructuring costs incurred to date 3,200     3,200 3,200
Restructuring charge (credit) 920 571 $ 1,400   2,900
Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Expected cost 1,400     1,400 1,400
Manufacturing Optimization Program [Member] | Biopharma [Member]          
Restructuring Cost and Reserve [Line Items]          
Restructuring costs incurred to date 1,100     1,100 $ 1,100
Restructuring charge (credit) $ (288) $ 1,200   $ 875  
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $691 million for 2025 (including charges of $920 million for our Realigning our Cost Base Program and credits of $288 million for our Manufacturing Optimization Program), (ii) charges of $1.8 billion for 2024 (including charges of $1.2 billion our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program) and (iii) charges of $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed). For 2025 and 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.